

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	10553627
<b>Application Number:</b>	10565713
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7929
<b>Title of Invention:</b>	Substituted 2-aminotetralin for the treatment of depression
<b>First Named Inventor/Applicant Name:</b>	Dieter Scheller
<b>Customer Number:</b>	28997
<b>Filer:</b>	Molly Banahan Edwards/Lisa Buchhold
<b>Filer Authorized By:</b>	Molly Banahan Edwards
<b>Attorney Docket Number:</b>	6102-000008/US/NP
<b>Receipt Date:</b>	19-JUL-2011
<b>Filing Date:</b>	25-JAN-2006
<b>Time Stamp:</b>	17:15:27
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	4171
Deposit Account	080750
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment/Req. Reconsideration-After Non-Final Reject	Response_to_Office_Action_dated_19_April_2011.PDF	135970 8f7956f9d83c40d07018c3e179183c4d2917	no	16
<b>Warnings:</b>					
<b>Information:</b>					
2	Non Patent Literature	Belluzzi1984_Abstract.PDF	36807 c785e806e959299a7f195132aa17e9d92a03	no	1
<b>Warnings:</b>					
<b>Information:</b>					
3	Non Patent Literature	Beaulieu1984_Abstract.PDF	79045 a6d21ef7cd05675a8c381b7bee8d57d77cd61	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	Non Patent Literature	BertainaAnglade2006.PDF	323012 84673177a8c5780c9d7b1805d0db05e00eac31	no	9
<b>Warnings:</b>					
<b>Information:</b>					
5	Non Patent Literature	Corrigan2000.PDF	780687 a04c2461e629d02d17ef93d06e84ca1403f2370e	no	8
<b>Warnings:</b>					
<b>Information:</b>					
6	Non Patent Literature	Goetz2003.PDF	1070342 cd0b79e4257818815674800a3959821e49c32d0b0	no	13
<b>Warnings:</b>					
<b>Information:</b>					
7	Non Patent Literature	Muscat1992_Abstract.PDF	80998 4d1c29ac931d0c484c4c02d01773d9200a2aac7	no	1
<b>Warnings:</b>					
<b>Information:</b>					
8	Non Patent Literature	Mayoclinic_Rotigotine2007.PDF	307336 a56b04d8bcca05d1c4d9f022d3db41bc1887e598	no	8

Warnings:					
Information:					
9	Non Patent Literature	Scheller2009.PDF	402765 cf4139661e667b107f8098ccfc445687b483ca	no	14
Warnings:					
Information:					
10	Non Patent Literature	Wang2007.PDF	525862 d6290af7298c54bc7cc08c530d4db4828ca4bb7	no	8
Warnings:					
Information:					
11	Non Patent Literature	Wikipedia_Apomorphine_printed_May_05_2011.PDF	99270 8846744200e6b007c1604c7878367a60f02f	no	6
Warnings:					
Information:					
12	Non Patent Literature	000078USOA1112002.PDF	359418 a30227b56c46188012c793d6f9f98c9785a8a8b	no	10
Warnings:					
Information:					
13	Non Patent Literature	000078USDVAOA9132007.PDF	536349 6e6dd61af3adec98748b76a3783358ba7071acf	no	14
Warnings:					
Information:					
14	Non Patent Literature	000078USDVAOA512008.PDF	758366 2d1bb4b1236d8f74ac2e02eb2e6cf623ee667f5	no	21
Warnings:					
Information:					
15	Non Patent Literature	000034USNPOA10162008.PDF	6846058 27ab62dc9f3c10e4531eebdc552f70bb4d8f96dc	no	132
Warnings:					
Information:					
16	Non Patent Literature	000078USDVAOA1262009.PDF	4028454 1ee9804f297d805376620802b6a01c3e375cbb1f7	no	93
Warnings:					
Information:					
17	Non Patent Literature	000034USNPOA922009.PDF	396622 30234678919546c35485f9a00eb9d4f9d55d0d7	no	11

Warnings:

Information:					
18	Non Patent Literature	000009USNPOA10232009.PDF	386450 3f5ec946ac1304071918894bcac06c4d07d6f6083	no	12
Warnings:					
Information:					
19	Non Patent Literature	000078USDVAOA1162009.PDF	1190805 048860001e110511512c70c8bb2bdc6083c692f	no	32
Warnings:					
Information:					
20	Non Patent Literature	000009USNPOA05272010.PDF	506423 b3fcd0125e614a638c54c912c0b381fdac4c9378	no	15
Warnings:					
Information:					
21	Non Patent Literature	000034USNPOA6072010.PDF	660243 54c764091e9e07d6c5a6a005908a5d2bc9204b6	no	15
Warnings:					
Information:					
22	Non Patent Literature	000078USDVAOA1082010.PDF	989048 8015688bc129ac815db260336d31702923a5b9574	no	25
Warnings:					
Information:					
23	Non Patent Literature	000009USNPOA02142011.PDF	630491 009c4cb9f8f1bb15008bf0510eacdc99d9f259	no	18
Warnings:					
Information:					
24		SupplementalIDS_with_Form1449.PDF	55212 e16c5d3715d6c9f500bc0185014c94bda04fb3363	yes	4
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	2	
	Information Disclosure Statement (IDS) Form (SB08)		3	4	
Warnings:					
Information:					

25	Fee Worksheet (5B06)	fee-info.pdf	30024 H0t0bedc367a7a3ba7Pba781f6f11daa130e52a70	no	2
<b>Warnings:</b>					
<b>Information:</b>					
Total Files Size (in bytes):			21216057		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					